

Bio-pharma product launches

The 10 most-anticipated drug launches of 2020

Company	Drug	Indication	Expected launch date
AstraZeneca, Daiichi Sankyo	Enhertu	HER2-positive breast cancer	Q1-2020 in US
Bristol-Myers Squibb	Ozanimod	Multiple sclerosis	End 2020 in US
Novartis	Inclisiran	High LDL cholesterol	2020 in US
FibroGen, AstraZeneca and Astellas (Japan)	Evrenzo (Roxadustat)	Anemia associated with kidney disease	2020 in US
Immunomedics	Sacituzumab Govitecan	Triple-negative breast cancer	Mid-2020 in US
Gilead Sciences	Filgotinib	Rheumatoid arthritis	2020 in US
Aimmune	Palforzia (AR101)	Peanut allergy	Early 2020
BioMarin Pharmaceutical	Valoctocogene Roxaparvovec	Hemophilia A	2020 in US
Biohaven Pharmaceutical	Rimegepant	Migraine	2020 in US
Roche	Risdiplam	Spinal muscular atrophy	2020 in US

Source: FiercePharma by Kyle Blankenship, Angus Liu